Intervacc work with an active patent strategy, which implies that applications for patents and trademark protection are submitted in the countries that are considered to have great market potential or are considered to be key markets for the product in question.

The company own four published patent families. The published patent families include a total of about 20 issued patents in various countries and further patents pending.

The four published patent families are:

  • Trivac, WO 2004/032957 A1, (priority year 2002).
    Patents granted and in force in Europe and USA.
  • Penta/Septavacc, WO 2009/075646 A1, (priority year 2007).
    Patents granted and in force in Europe and USA.
  • Strangvac® , WO 2011/149419 A1 (priority year 2010)
    Patents granted and in force in Europe, USA (US 9,333,252 and US 9,795,664), Hong Kong, China and Australia
  • S.suis vaccine, WO 2017/005913 A1 (priority year 2015)
    Patent granted in USA (US 11,155,585) and application in progress in Europe.

The primary purpose of the patents is related to protecting the company’s vaccine product Strangvac®.

In addition, one patent application describes the possibility of developing vaccine products against diseases caused by Streptococcus zooepidemicus. The application describes in detail the various vaccine components, and the development and application method. Furthermore, the application also describes different combinations of vaccine formulations tested in animal experiments including mouse and horse.

In addition to patents, the trademark for the vaccine Strangvac® is registered as an approved drug name.